SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
Turning a patient’s cells into targeted cancer fighters presents manufacturing challenges that big pharmaceutical companies and upstart biotechs are trying to address. The cell therapy field is also ...
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 7, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", Nasdaq: GRCL), a global clinical-stage biopharmaceutical ...
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) ...
Gracell Bio stands to benefit from tax credits and marketing exclusivity following receipt of ‘orphan drug’ status for its CAR-T cancer treatment Analysts see profitability several years away as ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical ...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (GRCL), a global clinical-stage biopharmaceutical company dedicated to developing ...
Oversubscribed transaction led by Vivo Capital and joined by leading healthcare investors including Adage Capital Partners LP, Exome Asset Management, Janus Henderson Investors, Logos Capital, OrbiMed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results